Genfit is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for metabolic, inflammatory and fibrotic diseases. Headquartered in Lille, France, the company has established itself as a leader in nonalcoholic steatohepatitis (NASH) research, leveraging its expertise in nuclear receptor biology. Since its founding in 1999, Genfit has built a diversified pipeline targeting key pathways implicated in chronic liver diseases and other metabolic disorders.
The company’s flagship asset, lanifibranor, is designed to activate multiple nuclear receptors to address inflammation, metabolic dysfunction and fibrosis in NASH patients. In parallel, Genfit is advancing other programs aimed at fibrotic conditions of the liver, lung and kidney, as well as cardiovascular and renal diseases. Its development strategy combines robust preclinical science with adaptive clinical trial designs to accelerate proof-of-concept and potential registration studies.
Genfit conducts operations in Europe and North America, collaborating with academic centers, contract research organizations and pharmaceutical partners to extend its research reach and optimize clinical development. The company’s partnerships bolster its R&D capabilities, allowing access to diverse patient populations and specialized expertise. Genfit also maintains a presence in Asia through regional distribution agreements and investigator-sponsored trials.
Under the leadership of Chief Executive Officer Pascal Prigent, Genfit has grown from a small research team into a multinational organization with a strong scientific advisory board and experienced management. The company’s governance structure emphasizes transparency and rigorous clinical oversight, supporting its long-term goal of bringing innovative therapies to patients with high unmet medical needs.
AI Generated. May Contain Errors.
